GSK Singapore

PES has been awarded the full C&Q scope of work for the S$343 million vaccines expansion project at GSK Biological’s vaccine facility in Tuas, Singapore. The new facility will manufacture drug substances for GSK’s vaccines that protect against Hepatitis B. “Having been involved personally in the commissioning and qualification of this greenfield facility back in 2007 – 2008, PES is delighted to have been chosen by GSK for this key project” – Gearoid Cronin, C&Q Director, PES. The project is due for completion in 2026.